SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001193125-19-190741
Filing Date
2019-07-09
Accepted
2019-07-08 21:25:02
Documents
1

Document Format Files

Seq Description Document Type Size
1 SC 13D/A d776383dsc13da.htm SC 13D/A 33054
  Complete submission text file 0001193125-19-190741.txt   34690
Mailing Address 101 MONTGOMERY STREET, SUITE 2550 SAN FRANCISCO CA 94104
Business Address 101 MONTGOMERY STREET, SUITE 2550 SAN FRANCISCO CA 94104 650-391-9740
Eidos Therapeutics, Inc. (Subject) CIK: 0001731831 (see all company filings)

IRS No.: 463733671 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-90540 | Film No.: 19946234
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences

Mailing Address 421 KIPLING STREET PALO ALTO CA 94301
Business Address 421 KIPLING STREET PALO ALTO CA 94301 (650) 391-9740
BridgeBio Pharma, Inc. (Filed by) CIK: 0001743881 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences